Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Total Assets of $1.47 billion for the year ending 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +1.8% in Total Assets from 2024 to 2025.
- This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $271.94 million | Q2 2021: $698.59 million | Q3 2021: $658.61 million | Q1 2022: $734.32 million | Q2 2022: $672.52 million | Q3 2022: $611.53 million | Q1 2023: $627.37 million | Q2 2023: $666.70 million | Q3 2023: $630.83 million | Q1 2024: $557.85 million | Q2 2024: $775.86 million | Q3 2024: $726.50 million | Q1 2025: $1.31 billion | Q2 2025: $1.30 billion | Q3 2025: $1.40 billion.
- Over the full 6 years of available data (2020 to 2025), RECURSION PHARMACEUTICALS, INC.'s Total Assets has grown by 393.7%.
- Historical annual values: Fiscal year 2025: $1.47 billion | Fiscal year 2024: $1.45 billion | Fiscal year 2023: $653.70 million | Fiscal year 2022: $701.29 million | Fiscal year 2021: $610.35 million | Fiscal year 2020: $298.59 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: